RALLIS CHRIS A 4
4 · FENNEC PHARMACEUTICALS INC. · Filed Feb 14, 2025
Insider Transaction Report
Form 4
RALLIS CHRIS A
Director
Transactions
- Exercise/Conversion
Common Shares
2025-02-14$2.51/sh+1,992$5,000→ 54,206 total - Sale
Common Shares
2025-02-14$6.82/sh−1,186$8,089→ 53,020 total - Exercise/Conversion
Common Shares
2025-02-14$2.51/sh−1,992$5,000→ 182,706 totalExercise: $2.51From: 2015-03-16Exp: 2025-03-16→ Options (1,992 underlying)
Footnotes (3)
- [F1]Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023.
- [F2]Shares sold to satisfy tax obligation on option exercise.
- [F3]Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023.